After the bonanza of 2021, life-sciences entrepreneurs reset their expectations as financing contracted
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelyrin, Adcendo, Algernon, Bayer, Boehringer Ingelheim, Caris, Celmatix, Duality, Esperovax, Evotec, Ginkgo, Lumen, Merck & Co., Nouscom, Orbit, Orna, Paratek, Phoremost, Sanegene, Simnova Xianbo, Triumvira, Variational Ai, Xencor, Y-Mabs.
